Activation of AR sensitizes breast carcinomas to NVP-BEZ235's therapeutic effect mediated by PTEN and KLLN upregulation

Molecular Cancer Therapeutics

Volumn 13, Issue 2, 2014, Pages 517-527

  Wang, Yu ^a   Yu, Qi ^a   He, Xin ^a   Romigh, Todd ^a   Altemus, Jessica ^a   Eng, Charis ^a,b,c,d,e  

^a Genomic Medicine Institute   (United States)

^b Taussig Cancer Institute   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d Department of Genetics and Genome Sciences ^*  (United States)

^e CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ANDROSTANOLONE; ANTINEOPLASTIC AGENT; AR PROTEIN, HUMAN; DACTOLISIB; IMIDAZOLE DERIVATIVE; KILLIN PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PTEN PROTEIN, HUMAN; QUINOLINE DERIVATIVE; TUMOR SUPPRESSOR PROTEIN;

ANIMAL; APOPTOSIS; BREAST NEOPLASMS; CELL PROLIFERATION; CELL SURVIVAL; DRUG EFFECTS; DRUG POTENTIATION; DRUG SCREENING; FEMALE; GENETICS; HUMAN; MCF 7 CELL LINE; METABOLISM; NUDE MOUSE; TIME; TUMOR CELL LINE; UPREGULATION; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DIHYDROTESTOSTERONE; DRUG SYNERGISM; FEMALE; HUMANS; IMIDAZOLES; MCF-7 CELLS; MICE, NUDE; PTEN PHOSPHOHYDROLASE; QUINOLINES; RECEPTORS, ANDROGEN; TIME FACTORS; TUMOR SUPPRESSOR PROTEINS; UP-REGULATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84894150029     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-13-0655     Document Type: Article

References (46)

1. Wang Y, Mikhailova M, Bose S, Pan CX, deVere White RW, GhoshPM. Regulation of androgen receptor transcriptional activity by rapamycin in prostate cancer cell proliferation and survival. Oncogene 2008; 27:7106-17.
2. Breuleux M, Klopfenstein M, Stephan C, Doughty CA, Barys L, Maira SM, et al. Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition. Mol Cancer Ther 2009; 8:742-53.
3. Lin HK, Hu YC, Lee DK, Chang C. Regulation of androgen receptor signaling by PTEN (phosphatase and tensin homolog deleted on chromosome 10) tumor suppressor through distinct mechanisms in prostate cancer cells. Mol Endocrinol 2004;18:2409-23.
4. Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, et al. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res 2008;68:8022-30.
5. Brachmann SM, Hofmann I, Schnell C, Fritsch C, Wee S, Lane H, et al. Specific apoptosis induction by the dual PI3K/mTor inhibitor NVPBEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells. Proc Natl Acad Sci U S A 2009;106:22299-304.
6. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011;121:2750-67.
7. Greeve MA, Allan RK, Harvey JM, Bentel JM. Inhibition of MCF-7 breast cancer cell proliferation by 5alpha-dihydrotestosterone; a role for p21(Cip1/Waf1). J Mol Endocrinol 2004;32:793-810.
8. Lanzino M, Sisci D, Morelli C, Garofalo C, Catalano S, Casaburi I, et al. Inhibition of cyclin D1 expression by androgen receptor in breast cancer cells-identification of a novel androgen response element. Nucleic Acids Res 2010;38:5351-65.
9. Wang Y, Romigh T, He X, Tan MH, Orloff MS, Silverman RH, et al. Differential regulation of PTEN expression by androgen receptor in prostate and breast cancers. Oncogene 2011;30:4327-38.
10. Agoff SN, Swanson PE, Linden H, Hawes SE, Lawton TJ. Androgen receptor expression in estrogen receptor-negative breast cancer. Immunohistochemical, clinical, and prognostic associations. Am J Clin Pathol 2003;120:725-31.
11. Ogawa Y, Hai E, Matsumoto K, Ikeda K, Tokunaga S, Nagahara H, et al. Androgen receptor expression in breast cancer: relationship with clinicopathological factors and biomarkers. Int J Clin Oncol 2008; 13:431-5.
12. Eng C. PTEN: one gene, many syndromes. Hum Mutat 2003;22: 183-98.
13. Wang Y, He X, Ngeow J, Eng C. GATA2 negatively regulates PTEN by preventing nuclear translocation of androgen receptor and by androgen- independent suppression of PTEN transcription in breast cancer. Hum Mol Genet 2012;21:569-76.
14. He X, Ni Y, Wang Y, Romigh T, Eng C. Naturally occurring germline and tumor-associated mutations within the ATP-binding motifs of PTEN lead to oxidative damage of DNA associated with decreased nuclear p53. Hum Mol Genet 2011;20:80-9.
15. Lacroix M, Toillon RA, Leclercq G. p53 and breast cancer, an update. Endocr Relat Cancer 2006;13:293-325.
16. Hollestelle A, Elstrodt F, Nagel JH, Kallemeijn WW, Schutte M. Phosphatidylinositol- 3-OH kinase or RAS pathway mutations in human breast cancer cell lines. Mol Cancer Res 2007;5:195-201.
17. Weigelt B, Warne PH, Downward J. PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs. Oncogene 2011;30:3222-33.
18. Moore NL, Buchanan G, Harris JM, Selth LA, Bianco-Miotto T, Hanson AR, et al. An androgen receptor mutation in the MDA-MB-453 cell line model of molecular apocrine breast cancer compromises receptor activity. Endocr Relat Cancer 2012;19:599-613.
19. Bennett KL, Mester J, Eng C. Germline epigenetic regulation of KILLIN in Cowden and Cowden-like syndrome. JAMA 2010;304:2724-31.
20. Cho YJ, Liang P. Killin is a p53-regulated nuclear inhibitor of DNA synthesis. Proc Natl Acad Sci U S A 2008;105:5396-401.
21. Wang Y, He X, Yu Q, Eng C. Androgen receptor-induced tumor suppressor, KLLN, inhibits breast cancer growth and transcriptionally activates p53/p73-mediated apoptosis in breast carcinomas. Hum Mol Genet 2013;22:2263-72.
22. WangY, Radhakrishnan D, He X, Peehl DM, Eng C. Transcription factor KLLN inhibits tumor growth by AR suppression, induces apoptosis by TP53/TP73 stimulation in prostate carcinomas, and correlates with cellular differentiation. J Clin Endocrinol Metab 2013;98:E586-94.
23. Bieche I, Laurendeau I, Tozlu S, Olivi M, Vidaud D, Lidereau R, et al. Quantitation of MYC gene expression in sporadic breast tumors with a real-time reverse transcription-PCR assay. Cancer Res 1999; 59:2759-65.
24. Latil A, Vidaud D, Valeri A, Fournier G, Vidaud M, Lidereau R, et al. htert expression correlates with MYC over-expression in human prostate cancer. Int J Cancer 2000;89:172-6.
25. Ilic N, Utermark T, Widlund HR, Roberts TM. PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis. Proc Natl Acad Sci U S A 2011;108: E699-708.
26. Muellner MK, Uras IZ, Gapp BV, Kerzendorfer C, Smida M, Lechtermann H, et al. A chemical-genetic screen reveals a mechanism of resistance to PI3K inhibitors in cancer. Nat Chem Biol 2011;7:787-93.
27. Iwabuchi T, Maruyama T, Sei Y, Adachi K. Effects of immunosuppressive peptidyl-prolyl cis-trans isomerase (PPIase) inhibitors, cyclosporin A, FK506, ascomycin and rapamycin, on hair growth initiation in mouse: immunosuppression is not required for new hair growth. J Dermatol Sci 1995;9:64-9.
28. Tao Y, Kim J, Schrier RW, Edelstein CL. Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease. J Am Soc Nephrol 2005;16:46-51.
29. Xu CX, Li Y, Yue P, Owonikoko TK, RamalingamSS, Khuri FR, et al. The combination of RAD001 and NVP-BEZ235 exerts synergistic anticancer activity against non-small cell lung cancer in vitro and in vivo. PLoS ONE 2011;6:e20899.
30. Zafar I, Belibi FA, He Z, Edelstein CL. Long-term rapamycin therapy in the Han:SPRD rat model of polycystic kidney disease (PKD). Nephrol Dial Transplant 2009;24:2349-53.
31. Cao P, Maira SM, Garcia-Echeverria C, Hedley DW. Activity of a novel, dual PI3-kinase/mTor inhibitor NVP-BEZ235 against primary human pancreatic cancers grown as orthotopic xenografts. Br J Cancer 2009;100:1267-76.
32. Diaz-Gonzalez R, Kuhlmann FM, Galan-Rodriguez C, Madeira da Silva L, Saldivia M, Karver CE, et al. The susceptibility of trypanosomatid pathogens to PI3/mTOR kinase inhibitors affords a new opportunity for drug repurposing. PLoS Negl Trop Dis 2011;5:e1297.
33. Smith GC, Ong WK, Rewcastle GW, Kendall JD, Han W, Shepherd PR. Effects of acutely inhibiting PI3K isoforms and mTOR on regulation of glucose metabolism in vivo. Biochem J 2012;442:161-9.
34. Creighton CJ, Fu X, Hennessy BT, Casa AJ, Zhang Y, Gonzalez-Angulo AM, et al. Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+breast cancer. Breast Cancer Res 2010;12:R40.
35. Squillace RM, Miller D, Wardwell SD, Wang F, Clackson T, Rivera VM. Synergistic activity of the mTOR inhibitor ridaforolimus and the antiandrogen bicalutamide in prostate cancer models. Int J Oncol 2012; 41:425-32.
36. Lapointe J, Labrie C. Role of the cyclin-dependent kinase inhibitor p27 (Kip1) in androgen-induced inhibition of CAMA-1 breast cancer cell proliferation. Endocrinology 2001;142:4331-8.
37. de Launoit Y, Dauvois S, Dufour M, Simard J, Labrie F. Inhibition of cell cycle kinetics and proliferation by the androgen 5 alpha-dihydrotestosterone and antiestrogen N,n-butyl-N-methyl-11-[160 alpha-chloro- 30,17 beta-dihydroxy-estra-10,30,50-(100)triene-70 alpha-yl] undecanamide in human breast cancer ZR-75-1 cells. Cancer Res 1991;51: 2797-802.
38. Peters AA, Buchanan G, Ricciardelli C, Bianco-Miotto T, Centenera MM, Harris JM, et al. Androgen receptor inhibits estrogen receptoralpha activity and is prognostic in breast cancer. Cancer Res 2009; 69:6131-40.
39. Macedo LF, Guo Z, Tilghman SL, Sabnis GJ, Qiu Y, Brodie A. Role of androgens on MCF-7 breast cancer cell growth and on the inhibitory effect of letrozole. Cancer Res 2006;66:7775-82.
40. Doane AS, Danso M, Lal P, Donaton M, Zhang L, Hudis C, et al. An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene 2006;25:3994-4008.
41. Ni M, Chen Y, Lim E, Wimberly H, Bailey ST, Imai Y, et al. Targeting androgen receptor in estrogen receptor-negative breast cancer. Cancer Cell 2011;20:119-31.
42. Ando S, De Amicis F, Rago V, Carpino A, Maggiolini M, Panno ML, et al. Breast cancer: from estrogen to androgen receptor. Mol Cell Endocrinol 2002;193:121-8.
43. Szelei J, Jimenez J, Soto AM, Luizzi MF, Sonnenschein C. Androgeninduced inhibition of proliferation in human breast cancer MCF7 cells transfected with androgen receptor. Endocrinology 1997;138: 1406-12.
44. Lin HY, Sun M, Lin C, Tang HY, London D, Shih A, et al. Androgeninduced human breast cancer cell proliferation is mediated by discrete mechanisms in estrogen receptor-alpha-positive and -negative breast cancer cells. J Steroid Biochem Mol Biol 2009;113:182-8.
45. Birrell SN, Bentel JM, Hickey TE, Ricciardelli C, Weger MA, Horsfall DJ, et al. Androgens induce divergent proliferative responses in human breast cancer cell lines. J Steroid Biochem Mol Biol 1995;52:459-67.
46. Wang Y, Kreisberg JI, Bedolla RG, Mikhailova M, deVere White RW, Ghosh PM. A 90 kDa fragment of filamin A promotes Casodex-induced growth inhibition in Casodex-resistant androgen receptor positive C4- 2 prostate cancer cells. Oncogene 2007;26:6061-70.